|
|
|
| home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace |
|
|
 WHITE PAPERS |
|
Medpace
|
|
The Promise and Challenge of Adaptive Design in Oncology Trials
|
|
Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.
Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics
• Collaboration to accelerate development and manufacturing of Bispecific Antibody
• Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >> |
|
 |
White Papers |
 |
|
The Process of Informed Consent (written by ACRP)
CenterWatch
Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >> |
|
 |
Industry Events |
 |
2020 Avoca Quality and Innovation Summit
3-4 June 2020, Amsterdam, The Netherlands
The 2020 Avoca Quality and Innovation Summit will take place 3-4 June
2020, in Amsterdam, The Netherlands.
More info >> |
|
|
|
